Abstract 582P
Background
Leptomeningeal metastases (LM) is one of the most severe complications of NSCLC and always accompanied with poor prognosis. Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with high brain penetration and wide therapeutic window. This study aims to evaluate the efficacy and safety of furmonertinib at 240mg/day in EGFR mutated NSCLC patients with leptomeningeal metastases (LM).
Methods
Patients were diagnosed as LM according to EANO-ESMO criteria. The primary endpoint was overall survival (OS), time to treatment discontinuation (TTD) and clinical response rate were secondary endpoints. Clinical response rate assessed with improvement of neurologic symptoms or signs and changes in the performance status. LM were assessed by investigator according to RANO-LM radiologic criteria.
Results
Between May 2021 and August 2023, 31 patients at Henan Cancer Hospital were enrolled. 26 (83.9%) patients received EGFR-TKI therapy prior to receive furmonertinib, 19 (61.3%) patients received at least 2 lines treatment, 21 (67.7%) patients received other 3rd generation EGFR-TKI therapy. The median age was 58 years (range:36-75), 23 (74.2%) were females. 21 (67.7%) patients with ECOG 3. 23 OS events had occurred at the data cut-off (1 August 2023), Median OS was 8.433 months (95%CI, 5.623 to 11.243) with 74.2% maturity. Median TTD was 7.633 months (95%CI, 3.688 to 11.579). The clinical response rate was 77.4%. The LM ORR and DCR assessed by investigator according to RANO-LM radiologic criteria were 54.2% and 95.8%, respectively. The safety profiles were consistent with previous reports for furmonertinib.
Conclusions
Furmonertinib 240mg/day has demonstrated clinically significant efficacy as first line and salvage therapy in patients with EGFR-mutant NSCLC and leptomeningeal metastases.
Clinical trial identification
ChiCTR2300072092.
Editorial acknowledgement
Legal entity responsible for the study
Qiming Wang.
Funding
Henan Province Health and Youth Subject Leader Training Project (No. [2020]60) The Excellent Young Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (No. YXKC2020046). Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer (No. [2021]10).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract